Jump to any asset
850 assets, updated daily
As of September 11, 2026, Orthofix Medical Inc. (OFIX) trades at $8.91. CleaRank Financial AI rates it Hold with a fair value of $13.00, 45.9% above the current price. Wall Street's consensus target is $13.00 across 5 analysts. RSI at 22 is in oversold territory, and the price is below its 50-day average of $10.61.
Orthofix Medical Inc. (OFIX)
Orthofix Medical Inc. NASDAQ
$8.91
0.2200 (2.53%)
At close: Sep 11, 4:00 PM EDT
AI Analyst Consensus
59 / 100
Orthofix Medical Inc. (OFIX) is trading at $8.91, below its 50-day and 200-day moving averages ($10.61 and $12.18), indicating a bearish technical trend. The stock's RSI is at 22.22, signaling oversold conditions that could precede a bounce. Despite negative EPS of -1.48, insiders are net sellers, investing $5.5 million versus $3.7 million in sales, suggesting some internal confidence. Wall Street analysts maintain a 'Hold' consensus with a median price target of $13.00, implying a 45.9% upside potential. The company operates in the Medical Devices industry within Healthcare, a sector with a median P/E of -6.02 and revenue growth of 8.1%. OFIX's revenue growth of 3.8% lags the sector average, and its negative EPS further complicates valuation. However, the recent earnings surprise of 333.33% in August 2026, with actual EPS of $0.07 against an estimate of -$0.03, offers a glimmer of positive operational momentum. The significant insider selling, particularly from ENGINE CAPITAL MANAGEMENT, L.L.C., warrants attention as a potential catalyst for a turnaround.
OFIX Price Analysis
Market Metrics
Open
$8.83
Day Range
$8.62 to $8.99
Prev Close
$8.69
Volume
30.4K
52-Week Range
$8.62 to $16.99
Market Cap
$360.16M
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, OFIX trades at 0.4323x, far below the sector average of 3.70x.
OFIX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 2 quarters, OFIX beat estimates 1 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
OFIX Analysis
Company's Health
3/5
AI Technical Analysis
Orthofix Medical Inc. is trading below its 50-day SMA of $10.61 and its 200-day SMA of $12.18, indicating a bearish trend. The RSI is at 22.22, firmly in oversold territory, suggesting potential for a short-term rebound. MACD is at -0.46, also pointing to bearish momentum, while the CCI at -124.81 reinforces the oversold condition. Volume has been significantly below average, down 90.3% compared to its average of 314,740, which could limit the impact of any potential upward price movement. The current price action suggests that key moving averages are acting as resistance. Investors should watch for a sustained break above the 50-day SMA to signal a potential shift in momentum.
ProTips
- Monitor upcoming earnings reports closely for continued EPS beats and revenue growth acceleration to validate the recent positive surprise.
- Given the oversold RSI, consider that a short-term technical bounce is possible, but fundamental improvements are needed for sustained upside.
- The significant insider buying provides a degree of confidence, but investors should still exercise caution due to the company's negative profitability and below-sector-average growth metrics.
Key Catalysts
Bullish
Significant Insider Net Buying
Insiders have invested $5.5 million in net purchases, indicating a degree of confidence in the company's future prospects, particularly from ENGINE CAPITAL MANAGEMENT, L.L.C.
Source: Insider TransactionsBullish
Strong Earnings Beat
The Q2 2026 earnings report showed a 333.33% EPS surprise ($0.07 actual vs. -$0.03 estimate), driving a positive stock reaction and suggesting improving operational efficiency.
Source: Earnings ReportNeutral
Wall Street 'Hold' Consensus
With a median price target of $13.00, analysts suggest a 45.9% upside, but the 'Hold' rating indicates a balanced view on the stock's near-term prospects.
Source: Analyst RatingsBearish
Negative EPS and Below-Sector Revenue Growth
The company continues to report negative EPS and its revenue growth lags behind the healthcare sector median, posing a fundamental challenge to valuation.
Source: Financial StatementsMarket Outlook
Orthofix Medical Inc. faces a challenging outlook, with its current price action and negative EPS suggesting continued pressure unless operational improvements gain significant traction. The median analyst target price of $13.00 implies a potential upside of 45.9%, but this is contingent on the company achieving sustained profitability and accelerating revenue growth towards sector averages. Key catalysts for a positive shift would include continued strong earnings beats, successful integration of acquired businesses, and positive clinical trial data or product approvals. Conversely, a failure to improve margins, increased competition, or a slowdown in the medical device market could lead to further downside, potentially testing the lower end of analyst targets and long-range projections.
Key Statistics
| Market Cap | 360.16M |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -1.48 |
| Dividend Yield | 0.00% |
| 52 Week High | 16.99 |
| 52 Week Low | 8.62 |
Orthofix Medical Inc. exhibits a challenging fundamental profile, with a negative EPS of -1.48 rendering its P/E ratio of -3.82 (negative due to EPS of $-1.48). The company's revenue growth of 3.8% is below the Healthcare sector's median of 8.1%. While the recent earnings report showed a significant positive surprise of 333.33% ($0.07 actual vs. -$0.03 estimate), this follows a pattern of mixed results and does not yet translate to overall profitability. The valuation appears stretched given the lack of profitability and below-average growth. However, the median analyst price target of $13.00 suggests that Wall Street sees potential for recovery, offering a 45.9% upside from the current price. The significant insider net buying, totaling $5.5 million, could indicate management's belief in the company's turnaround potential, despite current financial metrics.
Earnings & Growth Analysis
Orthofix Medical Inc. reported a substantial earnings beat in its most recent quarter ending August 5, 2026, with actual EPS of $0.07 significantly exceeding the estimated -$0.03, a 333.33% surprise. This positive result followed a period of mixed earnings, including a break-even quarter and a prior miss. The stock saw a 1.73% price increase following this latest earnings announcement, suggesting a favorable market reaction to the improved performance.
Key Risks
Orthofix Medical Inc. faces significant risks including its persistent negative EPS and below-sector-average revenue growth, which challenge its long-term profitability and valuation. The stock is trading below key moving averages, indicating a bearish technical trend that could continue if fundamental improvements do not materialize. Also, while recent insider buying is a positive signal, the overall financial health and path to consistent profitability remain key concerns for investors.
Technical Indicators
| RSI (14) | 22.22 |
|---|---|
| MACD | -0.46 |
| SMA 50 | 10.61 |
| SMA 200 | 12.18 |
RSI
Oversold
SMA Cross
Bearish
Price vs SMA
Bearish
MACD
Bearish
Moving averages show a lagging Death Cross (50-day: $10.61, 200-day: $12.18), price is trading below the 50-day SMA, RSI at 22.2 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.34
Weak correlation
Nasdaq 100 (QQQ)
+0.24
Weak correlation
Bitcoin (BTC)
-0.05
Weak correlation
Gold (XAU)
-0.04
Weak correlation
Check Custom Correlation
Calculating correlation...
OFIX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$8.821
Slight discount to current
Wait for small dip
AGGRESSIVE
$8.910
At current price
Enter now if confident
Risk Management
STOP LOSS
$8.142
MAX LOSS
-7.7%
Volatility-Adjusted Stop Loss
Calculated based on RSI (22.2) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$9.086
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$9.262
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$9.527
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
OFIX is classified as a high-volatility asset (Daily Vol: 3.25%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in OFIX in September 2016 would be worth about $1,983 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in OFIX today could grow to about $5,601 by 2036 in the base case, with a bull case near $30,358 and a bear case around $1,034. Projections are statistical simulations, not guarantees.
OFIX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $7.07 for OFIX by 2030 in the base case, from $8.91 today (0.8x over 4 years). The downside path ends near $2.43. These are outcomes of a Monte Carlo simulation run on OFIX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $4.93 | $8.41 | $14.35 |
| 2028 | $3.73 | $7.93 | $16.90 |
| 2029 | $2.97 | $7.49 | $18.90 |
| 2030 | $2.43 | $7.07 | $20.58 |
| 2031 | $2.02 | $6.67 | $22.03 |
| 2032 | $1.70 | $6.29 | $23.30 |
| 2033 | $1.44 | $5.94 | $24.42 |
| 2034 | $1.24 | $5.60 | $25.41 |
| 2035 | $1.06 | $5.29 | $26.28 |
| 2036 | $0.9209 | $4.99 | $27.05 |
Method: 10,000 simulated price paths using OFIX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
OFIX Insider Trading Analysis
Bought
$5.5M
9 Transactions
Sold
$3.7M
22 Transactions
Insiders
19
Active Traders
Avg Transaction
$297.4K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 22, 2026 | JUNIPER INVESTMENT COMPANY, LLC
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 242.0K | $2.6M |
| Jun 20, 2018 | FUJIKAWA RAYMOND
Officer
|
Sell | 32.2K | $1.9M |
| Jun 18, 2018 | FINEGAN MICHAEL M
Officer
|
Sell | 30.0K | $1.8M |
| Feb 19, 2019 | BIANCHI DAVIDE
Officer
|
Sell | 24.4K | $1.6M |
| Sep 1, 2016 | FINEGAN MICHAEL M
Officer
|
Sell | 25.0K | $1.1M |
| Jun 19, 2018 | BIANCHI DAVIDE
Officer
|
Sell | 14.8K | $885.7K |
| Jun 9, 2016 | MASON BRADLEY R
Chief Executive Officer
|
Sell | 18.3K | $843.5K |
| Jul 3, 2018 | NIEMANN BRADLEY V
Officer
|
Sell | 11.3K | $641.4K |
| May 20, 2016 | GOODWIN ROBERT ALLEN II
Officer
|
Sell | 13.2K | $580.2K |
| May 14, 2019 | MASON BRADLEY R
Chief Executive Officer
|
Sell | 10.7K | $573.0K |
Page 1 of 1
Frequently Asked Questions
What is Orthofix Medical Inc.'s stock forecast for 2030?
Orthofix Medical Inc.'s stock forecast for 2030, based on Monte Carlo simulations, projects a base case price of $7.07, with a downside scenario at $2.43 and an upside scenario at $20.58. These figures represent statistical outcomes and are not guaranteed price targets.
Is Orthofix Medical Inc. stock a buy right now?
Orthofix Medical Inc. (OFIX) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $13.00, suggesting a 45.9% upside from its current price of $8.91. The stock is technically oversold, but its negative EPS and below-sector-average revenue growth present considerable risks.
What are the biggest risks facing Orthofix Medical Inc.?
The primary risks for Orthofix Medical Inc. include its ongoing negative earnings per share, revenue growth that lags its healthcare sector peers, and a bearish technical trend indicated by its position below key moving averages. The company's ability to achieve consistent profitability and outpace sector growth are critical factors.
How did Orthofix Medical Inc. perform in its latest earnings report?
In its latest earnings report on August 5, 2026, Orthofix Medical Inc. reported an EPS of $0.07, significantly beating the estimated -$0.03 by 333.33%. This positive surprise led to a 1.73% increase in the stock price.
What is the consensus rating for OFIX stock?
The consensus rating for OFIX stock among Wall Street analysts is 'Hold', supported by a consensus score of 70 out of 100. This rating reflects a balanced view among the five analysts covering the company.
Are insiders buying Orthofix Medical Inc. stock?
Yes, insiders are net sellers of Orthofix Medical Inc. stock, with total purchases of $5.5 million compared to $3.7 million in sales. This activity, particularly from ENGINE CAPITAL MANAGEMENT, L.L.C., has resulted in a 'Slight Buy Signal' according to insider transaction data.
How does Orthofix Medical Inc. compare to its sector averages?
Orthofix Medical Inc.'s revenue growth of 3.8% is below the Healthcare sector median of 8.1%, and its P/E ratio of -6.02 (negative due to EPS of $-1.48). Its Return on Equity (ROE) is also negative compared to the sector's median of 6.9%.